Beijing SL Pharmaceutical Co., Ltd.

SZSE:002038 Stok Raporu

Piyasa değeri: CN¥7.4b

Beijing SL Pharmaceutical Gelecekteki Büyüme

Future kriter kontrolleri 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Beijing SL Pharmaceutical.

Anahtar bilgiler

n/a

Kazanç büyüme oranı

n/a

EPS büyüme oranı

Biotechs kazanç büyümesi44.8%
Gelir büyüme oranın/a
Gelecekteki özkaynak getirisin/a
Analist kapsamı

None

Son güncellemen/a

Gelecekteki son büyüme güncellemeleri

Recent updates

Beijing SL Pharmaceutical (SZSE:002038) Is Increasing Its Dividend To CN¥0.15

Jul 02
Beijing SL Pharmaceutical (SZSE:002038) Is Increasing Its Dividend To CN¥0.15

Beijing SL Pharmaceutical Co., Ltd.'s (SZSE:002038) Popularity With Investors Is Under Threat From Overpricing

Jun 25
Beijing SL Pharmaceutical Co., Ltd.'s (SZSE:002038) Popularity With Investors Is Under Threat From Overpricing

Why Beijing SL Pharmaceutical's (SZSE:002038) Shaky Earnings Are Just The Beginning Of Its Problems

Apr 30
Why Beijing SL Pharmaceutical's (SZSE:002038) Shaky Earnings Are Just The Beginning Of Its Problems

Beijing SL Pharmaceutical Co., Ltd.'s (SZSE:002038) 25% Price Boost Is Out Of Tune With Earnings

Mar 06
Beijing SL Pharmaceutical Co., Ltd.'s (SZSE:002038) 25% Price Boost Is Out Of Tune With Earnings

Bu bölümde, yatırımcıların şirketin kâr elde etme kabiliyetini anlamalarına yardımcı olmak için genellikle profesyonel analistlerin fikir birliği tahminlerine dayanan gelir ve kazanç büyüme tahminlerini sunuyoruz. Ancak Beijing SL Pharmaceutical yeterli geçmiş veri sağlamadığından ve analist tahmini olmadığından, gelecekteki kazançları geçmiş verileri ekstrapole ederek veya analist tahminlerini kullanarak güvenilir bir şekilde hesaplanamaz.

SimplyWall St tarafından kapsanan şirketlerin %97'si geçmiş finansal verilere sahip olduğu için bu oldukça nadir bir durumdur.

Kazanç ve Gelir Büyüme Tahminleri

SZSE:002038 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (CNY Millions )
TarihGelirKazançlarSerbest Nakit AkışıFaaliyetlerden NakitAvg. Analist Sayısı
9/30/202478282141364N/A
6/30/2024827129187406N/A
3/31/2024967285241454N/A
12/31/20231,018417242460N/A
9/30/20231,000314139342N/A
6/30/20231,079386214404N/A
3/31/20231,072373252420N/A
1/1/20231,050234226390N/A
9/30/20221,128228252456N/A
6/30/20221,144290214444N/A
3/31/20221,237397231469N/A
1/1/20221,215426228465N/A
9/30/20211,184497258507N/A
6/30/20211,200469269552N/A
3/31/20211,171395184452N/A
12/31/20201,113365160416N/A
9/30/20201,29628764393N/A
6/30/20201,517327109376N/A
3/31/20201,759348232496N/A
12/31/20192,030487393666N/A
9/30/20192,192543412570N/A
6/30/20192,237578423599N/A
3/31/20192,193590349540N/A
1/1/20192,167571258485N/A
9/30/20182,019675285399N/A
6/30/20181,757651N/A385N/A
3/31/20181,456589N/A454N/A
12/31/20171,242534N/A383N/A
9/30/20171,085486N/A528N/A
6/30/20171,004431N/A454N/A
3/31/2017978430N/A415N/A
12/31/20161,010452N/A397N/A
9/30/20161,032443N/A373N/A
6/30/20161,090500N/A430N/A
3/31/20161,138545N/A405N/A
12/31/20151,157575N/A505N/A
9/30/20151,169653N/A453N/A
6/30/20151,195667N/A512N/A
3/31/20151,232705N/A536N/A
12/31/20141,243695N/A465N/A
9/30/20141,229668N/A546N/A
6/30/20141,204643N/A437N/A
3/31/20141,219617N/A468N/A
12/31/20131,162577N/A347N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: Insufficient data to determine if 002038's forecast earnings growth is above the savings rate (2.9%).

Kazançlar ve Piyasa: Insufficient data to determine if 002038's earnings are forecast to grow faster than the CN market

Yüksek Büyüme Kazançları: Insufficient data to determine if 002038's earnings are expected to grow significantly over the next 3 years.

Gelir ve Pazar: Insufficient data to determine if 002038's revenue is forecast to grow faster than the CN market.

Yüksek Büyüme Geliri: Insufficient data to determine if 002038's revenue is forecast to grow faster than 20% per year.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: Insufficient data to determine if 002038's Return on Equity is forecast to be high in 3 years time

Büyüyen şirketleri keşfedin

7D

1Y

7D

1Y

7D

1Y